Ke Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ke Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Zhi He
Department of Pharmacology, College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China
6 shared publications - Yue Chen
Department of Pharmacology, College of Medicine, Jiaxing University, Jiaxing, 314001, PR China
3 shared publications - Zicheng Li
Third-Grade Pharmacological Laboratory On Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, People’s Republic of China
3 shared publications - Bo Zhao
Third-Grade Pharmacological Laboratory On Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, People’s Republic of China
2 shared publications - Huai-Yu Liu
College of Medicine and Health Sciences, China Three Gorges University, Yichang, 443002, PR China
2 shared publications - Jing Chen
Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, China
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Harpagide attenuates cerebral ischemic injury by modulating mitochondrial calcium homeostasis associated with the AMPK–MCU axis
Mitochondrial calcium homeostasis may offer therapeutic benefits for ischemic stroke. Harpagide has been shown to inhibit mitochondrial calcium uptake, but the mechanism remains unclear. In this study, a male ICR mouse model of permanent middle cerebral artery occlusion (pMCAO)-induced focal cerebral ischemia and PC12 and SH-SY5Y cells exposed to oxygen–glucose deprivation (OGD) were used. Apoptosis, lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), and the ATP levels were measured to assess the neuroprotective effects of harpagide. DCFH-DA, JC-1, and Rhod-2A probes were used to analyze the mitochondrial function. RT-qPCR and western blot were used to determine the mitochondrial calcium uniporter (MCU), the apoptosis-inducing factor (AIF), Endo G, Cyt C, Caspase-3, and AMPK–MCU phosphorylation expression levels. Additionally, Longa scoring and triphenyl tetrazolium chloride (TTC) staining were used. Transmission electron microscopy (TEM) was used to examine the mitochondrial ultrastructural changes. An immunohistochemical analysis was conducted to detect the MCU expression in the temporal cortex. Harpagide attenuated OGD-induced cytotoxicity, as evidenced by reduced lactate LDH leakage, restored ATP generation, and ameliorated mitochondrial ultrastructural damage. Mechanistically, harpagide suppressed oxidative stress and alleviated mitochondrial calcium ([Ca 2+ ] mito ) overload, concomitant with modulated expression of MCU complex components and apoptosis-related proteins. These neuroprotective effects were linked to harpagide-mediated AMPK expression and subsequent preservation of mitochondrial bioenergetics and calcium homeostasis. Collectively, these findings position harpagide as a promising phytochemical candidate for ameliorating mitochondrial dysfunction in ischemic stroke, warranting further investigation into its precise molecular interactions with the AMPK–MCU axis.
- 1 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessHarpagide attenuates cerebral ischemic injury by modulating mitochondrial calcium homeostasis associated with the AMPK–MCU axis
Mitochondrial calcium homeostasis may offer therapeutic benefits for ischemic stroke. Harpagide has been shown to inhibit mitochondrial calcium uptake, but the mechanism remains unclear. In this study, a male ICR mouse model of permanent middle cerebral artery occlusion (pMCAO)-induced focal cerebral ischemia and PC12 and SH-SY5Y cells exposed to oxygen–glucose deprivation (OGD) were used. Apoptosis, lactate dehydrogenase (LDH), superoxide dismutase (SOD), malondialdehyde (MDA), and the ATP levels were measured to assess the neuroprotective effects of harpagide. DCFH-DA, JC-1, and Rhod-2A probes were used to analyze the mitochondrial function. RT-qPCR and western blot were used to determine the mitochondrial calcium uniporter (MCU), the apoptosis-inducing factor (AIF), Endo G, Cyt C, Caspase-3, and AMPK–MCU phosphorylation expression levels. Additionally, Longa scoring and triphenyl tetrazolium chloride (TTC) staining were used. Transmission electron microscopy (TEM) was used to examine the mitochondrial ultrastructural changes. An immunohistochemical analysis was conducted to detect the MCU expression in the temporal cortex. Harpagide attenuated OGD-induced cytotoxicity, as evidenced by reduced lactate LDH leakage, restored ATP generation, and ameliorated mitochondrial ultrastructural damage. Mechanistically, harpagide suppressed oxidative stress and alleviated mitochondrial calcium ([Ca 2+ ] mito ) overload, concomitant with modulated expression of MCU complex components and apoptosis-related proteins. These neuroprotective effects were linked to harpagide-mediated AMPK expression and subsequent preservation of mitochondrial bioenergetics and calcium homeostasis. Collectively, these findings position harpagide as a promising phytochemical candidate for ameliorating mitochondrial dysfunction in ischemic stroke, warranting further investigation into its precise molecular interactions with the AMPK–MCU axis.
- Open Access
- 26 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clonidine protects rat hippocampal and cortical neurons from oxygen-glucose deprivation and reoxygenation-induced injury through HCN Channels
The online version contains supplementary material available at 10.1038/s41598-026-44378-8.
- 26 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClonidine protects rat hippocampal and cortical neurons from oxygen-glucose deprivation and reoxygenation-induced injury through HCN Channels
The online version contains supplementary material available at 10.1038/s41598-026-44378-8.
- 6 March 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 364, 121463
A Novel Mechanism by which harpagide protects against cerebral ischemia:Focus on Grp75 and MAMs Calcium Homeostasis
- 6 March 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 364, 121463
A Novel Mechanism by which harpagide protects against cerebral ischemia:Focus on Grp75 and MAMs Calcium Homeostasis
- Open Access
- 25 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
ZD7288 ameliorates long-term cerebral ischemia reperfusion-induced deterioration of spatial memory by regulating the expressions of NMDA receptor subunits in rats
To study the effect of inhibition of hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) on spatial memory with cerebral ischemia-reperfusion (IR) in rats, the middle cerebral artery occlusion was performed to induce the IR injury. ZD7288 (5 µg/µl) and MK-801 (100 µg/µl) were administrated by lateral ventricular injection. Except for the sham group, all other groups were subjected to ischemia for 2 h followed by reperfusion for 4 weeks. The neurological impairment was evaluated using the neurological deficit score, and the Morris water maze detected changes in spatial memory. The cerebral infarction volume was determined by TTC staining, and the morphology and number of hippocampal neurons on the ischemic side were observed through HE staining. Immunoblotting and qPCR were used to detect the expressions of HCN1, HCN2, and N-methyl-D-aspartic acid receptor (NMDAR) subunits in the hippocampus. The expression changes of NMDAR subunits were applied by immunohistochemistry in different hippocampus regions. Our study found that ZD7288 could improve the spatial memory deficits induced by IR and exert neuroprotective effects. The possible mechanism is related to the fact that ZD7288 regulates the expression of various subunits of NMDAR by inhibiting HCN, including its effect on their phosphorylation states.
- 25 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessZD7288 ameliorates long-term cerebral ischemia reperfusion-induced deterioration of spatial memory by regulating the expressions of NMDA receptor subunits in rats
To study the effect of inhibition of hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) on spatial memory with cerebral ischemia-reperfusion (IR) in rats, the middle cerebral artery occlusion was performed to induce the IR injury. ZD7288 (5 µg/µl) and MK-801 (100 µg/µl) were administrated by lateral ventricular injection. Except for the sham group, all other groups were subjected to ischemia for 2 h followed by reperfusion for 4 weeks. The neurological impairment was evaluated using the neurological deficit score, and the Morris water maze detected changes in spatial memory. The cerebral infarction volume was determined by TTC staining, and the morphology and number of hippocampal neurons on the ischemic side were observed through HE staining. Immunoblotting and qPCR were used to detect the expressions of HCN1, HCN2, and N-methyl-D-aspartic acid receptor (NMDAR) subunits in the hippocampus. The expression changes of NMDAR subunits were applied by immunohistochemistry in different hippocampus regions. Our study found that ZD7288 could improve the spatial memory deficits induced by IR and exert neuroprotective effects. The possible mechanism is related to the fact that ZD7288 regulates the expression of various subunits of NMDAR by inhibiting HCN, including its effect on their phosphorylation states.
- 4 June 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (5) , 741-752
The alpha2-adrenergic receptor agonist clonidine protects against cerebral ischemia/reperfusion induced neuronal apoptosis in rats
Apoptosis is the crucial pathological mechanism following cerebral ischemic injury. Our previous studies demonstrated that clonidine, one agonist of alpha2-adrenergic receptor (α2-AR), could attenuate cerebral ischemic injury in a rat model of middle cerebral artery occlusion/reperfusion (MCAO/R). However, it’s unclear whether clonidine exerts neuroprotective effects by regulating neuronal apoptosis. In this study, we elucidated whether clonidine can exert anti-apoptotic effects in cerebral ischemic injury, and further explored the possible mechanisms. Neurological deficit score was measured to evaluate the neurological function. TTC staining was used for the measurement of brain infarct size. Hematoxylin-Eosin (HE) staining was applied to examine the cell morphology. TUNEL and DAPI fluorescent staining methods were used to analyze the cell apoptosis in brain tissue. Fluorescence quantitative real-time PCR was performed to assess the gene expression of Caspase-3 and P53. Western blotting assay was applied to detect the protein expression of Caspase-3 and P53. The results showed that clonidine improved neurological function, reduced brain infarct size, alleviated neuronal damage, and reduced the ratio of cell apoptosis in the brain with MCAO/R injury. moreover, clonidine down-regulated the gene and protein expression of Caspase-3 and P53 which were over-expressed after MCAO/R injury. Whereas, yohimbine (one selective α2-AR antagonist) mitigated the anti-apoptosis effects of clonidine, accompanied by reversed gene and protein expression changes. The results indicated that clonidine attenuated cerebral MCAO/R injury via suppressing neuronal apoptosis, which may be mediated, at least in part, by activating α2-AR.
- 4 June 2024
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 39 (5) , 741-752
The alpha2-adrenergic receptor agonist clonidine protects against cerebral ischemia/reperfusion induced neuronal apoptosis in rats
Apoptosis is the crucial pathological mechanism following cerebral ischemic injury. Our previous studies demonstrated that clonidine, one agonist of alpha2-adrenergic receptor (α2-AR), could attenuate cerebral ischemic injury in a rat model of middle cerebral artery occlusion/reperfusion (MCAO/R). However, it’s unclear whether clonidine exerts neuroprotective effects by regulating neuronal apoptosis. In this study, we elucidated whether clonidine can exert anti-apoptotic effects in cerebral ischemic injury, and further explored the possible mechanisms. Neurological deficit score was measured to evaluate the neurological function. TTC staining was used for the measurement of brain infarct size. Hematoxylin-Eosin (HE) staining was applied to examine the cell morphology. TUNEL and DAPI fluorescent staining methods were used to analyze the cell apoptosis in brain tissue. Fluorescence quantitative real-time PCR was performed to assess the gene expression of Caspase-3 and P53. Western blotting assay was applied to detect the protein expression of Caspase-3 and P53. The results showed that clonidine improved neurological function, reduced brain infarct size, alleviated neuronal damage, and reduced the ratio of cell apoptosis in the brain with MCAO/R injury. moreover, clonidine down-regulated the gene and protein expression of Caspase-3 and P53 which were over-expressed after MCAO/R injury. Whereas, yohimbine (one selective α2-AR antagonist) mitigated the anti-apoptosis effects of clonidine, accompanied by reversed gene and protein expression changes. The results indicated that clonidine attenuated cerebral MCAO/R injury via suppressing neuronal apoptosis, which may be mediated, at least in part, by activating α2-AR.